Document:

Subordinated Promissory Note (No. 201003-001)

 Exhibit 10.13 
 THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN
ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF A CURRENT AND EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS WITH RESPECT TO SUCH SECURITIES, OR
AN OPINION SATISFACTORY TO THE ISSUER AND ITS COUNSEL TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS. 
 AUTOGENOMICS, INC. 
 6.0% SUBORDINATED NOTE 

 

			
	No. 201003-001	  	Vista, California
	$500,000.00	  	March 9, 2010

 FOR VALUE RECEIVED, AutoGenomics, Inc., a Delaware corporation (the “Company”), hereby
promises to pay to the order of Elissa Kenna Trust or registered assigns (“Holder”), the principal amount of $500,000, together with interest thereon at the rate of six percent (6.0%) per annum based on a 365-day year and the
number of days elapsed, on or before March 10, 2012 (the “Maturity Date”), subject to the terms and conditions set forth below. This 6.0% Subordinated Note (this “Note”) has been issued pursuant to that certain
Subscription Agreement dated February 25, 2010, to which the Company and Holder are parties (the “Agreement”). Capitalized terms not defined herein have the meaning assigned to them in the Agreement. 

This Note is one of a series of 6.0% Subordinated Notes, due 2012, issued in one or more closings (collectively referred to herein as the
“Subordinated Notes”), all of like tenor, except as to the identifying number, principal amount, issue date and holder thereof. 
 1. Defined Terms. 
 “Affiliate” means, with regard to any
Person, (i) any Person, directly or indirectly, controlled by, under common control with, or controlling such Person, (ii) any Person, directly or indirectly, in which such Person holds, of record or beneficially, five percent
(5.0%) or more of the equity or voting securities, (iii) any Person that holds, of record or beneficially, five percent (5.0%) or more of the equity or voting securities of such Person, (iv) any Person that, through contract,
relationship or otherwise, exerts a substantial influence on the management of such Person’s affairs, (v) any director, officer, partner or individual holding a similar position in respect of such Person, or (vi) as to any natural
Person, any Person related by blood, marriage or adoption and any Person owned by such Persons. 

  
 1 

 “Indebtedness” means: 

(i) all indebtedness of the Company for monies borrowed from banks, trust companies, insurance companies and other
financial institutions, including commercial paper, letters of credit and accounts receivable sold or assigned by the Company to such institutions; 
 (ii) all indebtedness of the Company for monies borrowed by the Company from other persons or entities (excluding accrued expenses, trade payables, workers’ compensation claims, self-insurance
obligations, bankers’ acceptances, performance, hedging obligations and surety bonds in the ordinary course of business); 
 (iii) obligations of the Company as lessee under leases of real or personal property; 
 (iv) indebtedness or obligations of others of the kinds described above assumed or guaranteed in any manner by the Company; 

(v) deferrals, renewals, extensions and refundings of any such indebtedness or obligations described above; 

(vi) any balance deferred and unpaid of the purchase price of any property or services due more than six months after such
property is acquired or such services are completed; and 
 (vii) any other indebtedness of the Company which the
Company and the holders of more than 50% of the unpaid principal amount of the Subordinated Notes then outstanding may hereafter from time to time expressly and specifically agree in writing shall constitute Indebtedness; 

if and to the extent any of the preceding items (other than letters of credit and hedging obligations) would appear as a liability upon a balance sheet
of the specified person prepared in accordance with generally accepted accounting principals, whether or not contingent. In addition, the term “Indebtedness” includes all Indebtedness of others secured by a Lien on any asset of the Company
(whether or not such Indebtedness is assumed by the Company). 
 “Lien” means with respect to any assets, any
mortgage, lien, pledge, charge, security interest or other similar encumbrance (including, without limitation, any conditional sale or other title retention agreement or lease in the nature thereof, any option or other agreement to sell, and any
filing of or agreement to give, any security interest). 
 “Pari Passu Subordinated Notes” means the
Subordinated Notes and all other indebtedness of the Company represented by subordinated promissory notes ranking pari passu with and equal in right of payment to the Subordinated Notes. 

“Person” means any corporation, partnership, joint venture, limited liability company, organization, entity,
governmental authority, body or agency, or natural person. 

  
 2 

 “Senior Indebtedness” means any (i) Indebtedness designated by the
Company as ranking senior to the Subordinated Notes and (ii) any other indebtedness of the Company which the Company and the holders of more than 50% of the unpaid principal amount of the Subordinated Notes then outstanding may hereafter from
time to time expressly and specifically agree in writing shall constitute Senior Indebtedness, provided, however, that (a) the aggregate amount of all Senior Indebtedness at any one time outstanding shall not exceed $4.0 million; and
(b) the Company agrees to provide to the Holder, if requested, the names of the holders of all Senior Indebtedness in writing, and to provide the Holder, if requested, with copies of all agreements related to any such Senior Indebtedness.
Notwithstanding the foregoing, “Senior Indebtedness” shall not include (x) any other Indebtedness of the Company designated as subordinated indebtedness, including the other Subordinated Notes, which shall rank equally and ratably
with or subordinate to the Subordinated Notes, or (y) any Indebtedness of the Company owed to any Affiliate of the Company. 
 2. Subordination. 
 (a) Subordination to Senior Indebtedness. The
Indebtedness evidenced by this Note, and the payment of the principal hereof and interest hereon, (i) is wholly subordinated, junior and subject in right of payment, to the extent and in the manner hereinafter provided, to the prior payment of
all Senior Indebtedness and (ii) ranks pari passu in right of payment to all other indebtedness of the Company represented by subordinated promissory notes outstanding on the date hereof. 

(b) Rights of Holders Unimpaired. The provisions of this Section 2 are, and are intended solely, for the purposes of defining
the relative rights of the holders of the Subordinated Notes and the holders of Senior Indebtedness and nothing in this Section 2 shall impair, as between the Company and any holders of the Subordinated Notes, the obligation of the Company,
which is unconditional and absolute, to pay to the holders of the Subordinated Notes the principal thereof, in accordance with the terms of the Subordinated Notes, nor shall anything herein prevent any holders of the Subordinated Notes from
exercising all remedies otherwise permitted by applicable law or hereunder upon default, subject to the rights set forth above of holders of Senior Indebtedness to receive cash, property or securities otherwise payable or deliverable to the holders
of the Subordinated Notes. 
 3. Repayment of the Subordinated Notes. 

(a) Repayment at the Maturity Date. On the Maturity Date, the Company shall repay all, but not less than all, of the outstanding
principal amount of the Subordinated Notes due on such Maturity Date, and all accrued and unpaid interest thereon, by mailing a corporate check in such amount payable to the Holder at the Holder’s address of record as contained herein, or on
file with the Company pursuant to notice given as provided herein, no later than ten (10) business days after the Maturity Date or, at the request of the Holder, by wire transfer of immediately available funds designated in writing by the
Holder. 
 (b) Redemption Prior to the Maturity Date. The Company may redeem in whole or in part the Note, at any time or
from time to time, without penalty at a redemption price equal to 100% of the principal amount of Note, together with all accrued and unpaid interest 

  
 3 

 
thereon through the redemption date, provided that such redemption is on a pro rata basis with all other Subordinated Notes then outstanding (determined based on the aggregate principal
amount of all Subordinated Notes then outstanding as of such redemption date). 
 (c) Cancellation of Subordinated Note.
Immediately upon repayment in full of this Note, including all principal, accrued interest, redemption price, as applicable, and any amounts owed pursuant to paragraph 9(e) hereof, this Note shall no longer be deemed to be outstanding and all rights
with respect to this Note shall immediately cease and terminate as of the date of such repayment. 
 4. Covenants of the
Company. 
 (a) Incurrence of Additional Indebtedness. The Company shall not incur any Indebtedness after the date
hereof without the prior written consent of holders representing 75% of the aggregate principal amount of all then outstanding Pari Passu Subordinated Notes; provided, however, that without the consent of any of the holders of the
Subordinated Notes, the Company may incur: 
 (1) equipment financing, receivables-based financing and unsecured Indebtedness,
in an aggregate principal amount and/or aggregate borrowing capacity not to exceed $4.0 million at any one time outstanding, including any refinancings or replacements thereof, and 

(2) refinancing of Indebtedness outstanding as of the date hereof (which for the avoidance of doubt shall include the Subordinated
Notes), provided that (i) the principal amount of the refinancing indebtedness incurred pursuant to this clause (2) is not greater than the principal amount of the Indebtedness being refinanced, and (ii) the maturity date of
the refinancing indebtedness is not prior to the maturity date of the Indebtedness being refinanced. 
 The Company may
designate, at the time of incurrence, that Indebtedness incurred pursuant to this Section 4(a) may be incurred in whole or in part under either of clause (1) or (2), and may be redesignated from time to time at the Company’s sole and
absolute discretion. 
 (b) Reports. Until the Company becomes subject to the reporting requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934, at the request of the Holder, the Company agrees to furnish to the Holder the following financial statements and other information: 

(1) as soon as available, copies of the unaudited consolidated balance sheets of the Company and its subsidiaries as of
the end of the first three quarterly accounting periods during the fiscal year of the Company in which the Holder makes such request, and of the related consolidated statements of income and retained earnings and cash flows for such accounting
periods; 
 (2) as soon as available after the end of each fiscal year of the Company, copies of the audited
consolidated balance sheets of the Company and its subsidiaries as of the end of such fiscal year, and of the related audited consolidated 

  
 4 

 
statements of income and retained earnings and cash flows for such fiscal year accompanied by a report thereon from independent certified public accountants selected by the Company;
provided that the Company shall not be required to deliver audited financial statements if not otherwise required in connection with its financing agreements. 
 (c) Terms No More Favorable. If any of the other subordinated indebtedness issued by the Company after the date hereof contain terms more favorable to the holder of such subordinated indebtedness
than those contained in this Note (such subordinated indebtedness, the “More Favorable Terms Note”), the Company shall promptly (but not less than 5 days after the issuance of such More Favorable Terms Note) offer to exchange for
this Note a new Subordinated Note which shall have the same terms as this Note plus the more favorable terms of the More Favorable Terms Note. 
 5. Requirements for Transfer. This Note shall not be sold or transferred unless either (i) this Note shall have been registered or qualified under the Securities Act of 1933, as amended (the
“Act”), and all applicable state securities laws with respect thereto or (ii) the Company first shall have been furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale or
transfer is exempt from the registration or qualification requirements of the Act and all applicable state securities laws with respect thereto. 
 6. Payment of Principal. All payments due and payable from the Company to Holder under this Note shall be made in lawful currency of the United States of America. In no event shall any prepayment
of principal be made with respect to any other subordinated indebtedness of the Company unless and until the Company shall have concurrently prepaid a like proportionate amount of the principal of this Note. All repayments and prepayments under this
Note shall be applied first to accrued and unpaid interest and then to the outstanding principal balance hereof. 
 7.
Default. Upon the occurrence of an Event of Default (as defined below), the entire unpaid portion of the principal amount of this Note, and all accrued and unpaid interest due Holder hereunder, shall automatically become due and payable. As
used in this Note, “Event of Default” shall mean: (i) a receiver, trustee, custodian or similar officer is appointed for the Company, or for any substantial part of its property and such appointment or proceedings remain unstayed or
undismissed for a period of 90 days, (ii) any bankruptcy, insolvency, reorganization, arrangement, readjustment of debt, dissolution, liquidation or similar proceedings under the laws of any jurisdiction is instituted (by petition, application
or otherwise) against the Company and such appointment or proceedings remain unstayed or undismissed for a period of 90 days, (iii) the Company admits in writing its inability to pay its debts when due, (iv) the Company makes an assignment
for the benefit of creditors, (v) the Company applies for or consents to the appointment of any receiver, trustee, custodian or similar officer for the Company or for any substantial part of its property, (vi) the Company institutes (by
petition, application or otherwise) or consents to any bankruptcy, insolvency, reorganization, arrangement, readjustment of debt, dissolution, liquidation or similar proceedings under the laws of any jurisdiction against the Company, (vii) any
Indebtedness of the Company in excess of $1,000,000 is accelerated prior to its scheduled maturity date, (viii) the Company fails to make any principal or interest payment under this Note when due and, other than at scheduled maturity, such
breach remains 

  
 5 

 
uncured for 10 days following written notice from any holder of Subordinated Notes, and (ix) the Company breaches any of its other obligations hereunder or as set forth in the Agreement and
such breach remains uncured for thirty days following written notice from any holder of Subordinated Notes. 
 8.
Replacement. Whenever this Note shall be surrendered at the principal executive office of the Company for transfer or exchange, accompanied by a written instrument of transfer in form reasonably satisfactory to the Company duly executed by
the Holder hereof or his, her or its attorney duly authorized in writing, the Company shall execute and deliver in exchange therefor a new Note or Notes, as may be requested by such Holder, in the same aggregate unpaid principal amount and payable
on the same date as the principal amount of the Note or Notes so surrendered; each such new Note shall be in such principal amount and registered in such name or names as such Holder may designate in writing. Upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note and of indemnity reasonably satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and
cancellation of this Note (in case of mutilation) the Company will make and deliver in lieu of this Note a new Note of like tenor and unpaid principal amount. 
 9. General. 
 (a) Successors and Assigns. This Note, and the
obligations and rights of the Company hereunder, shall be binding upon and inure to the benefit of the Company, the Holder of this Note, and their respective heirs, successors and assigns. 

(b) Notices. All notices, requests, consents and demands shall be made in writing and shall be deemed effectively given:
(a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent
by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications
shall be sent to the Company at 2980 Scott Street, Vista, CA 92801, Attention: President, and to the Holder at the applicable address set forth on the applicable signature page to the Subscription Agreement or at such other address as the Company or
Holder may designate by ten (10) days advance written notice to the other parties hereto. 
 (c) Governing Law. This
Note shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of New York, without regard to its principles of choice of law. 

(d) Waiver and Amendment. No delay or omission on the part of the Holder in exercising any right under this Note shall operate as
a waiver of such right or of any other right of such Holder, nor shall any delay, omission or waiver on any one occasion be deemed a bar to or waiver of the same or any other right on any future occasion. The Company hereby waives presentment,
notice of dishonor, protest and notice of protest with respect to this Note. This Note may only be amended or modified by a written agreement signed by the Company and Holder. 

  
 6 

 (e) Costs of Collection. The Company agrees to pay on demand all costs of collection,
including reasonable attorney’s fees, incurred by the Holder in enforcing the obligations of the Company under this Note. 

(f) Confidentiality. By the Holder’s acceptance hereof, the Holder agrees to keep confidential and not disclose, divulge or
use for any unauthorized purpose any confidential, proprietary or secret information which the Holder may obtain from the Company and which is marked by the Company as confidential (i) pursuant to financial statements, reports and other
materials submitted by the Company to the Holder, or (ii) pursuant to visitation or inspection rights (if any) granted to the Holder, in each case, unless such information is known, or until such information becomes known, to the public, or the
Holder is required by any governmental agency, court or other regulatory body having jurisdiction over the Holder to disclose such information, but only for the sole purpose of and solely to the extent required by such agency, court or other
regulatory body, provided that the Holder, to the extent possible, shall give the Company prior written notice of the proposed disclosure and cooperate fully with the Company to minimize the scope of any such required disclosure, to the
extent possible and in accordance with applicable law. 
 (g) Headings. The headings in this Note are for purposes of
reference only and shall not limit or otherwise affect the meaning of any provision of this Note. 
 (Signature Page
Follows) 

  
 7 

 IN WITNESS WHEREOF, this Note has been executed and delivered on the date first above
written by the undersigned authorized representative of the Company. 
  

			
	 AUTOGENOMICS, INC.
 a Delaware corporation

		
	By:	 	 /s/ Fareed Kureshy

		 	Fareed Kureshy
		 	President and CEO

  
 (Signature
Page to Subordinated Note) 

 Schedule to Exhibit 10.13 

The following subordinated promissory notes are substantially identical in all material respects to the representative note to which this
schedule is attached and which is filed as an exhibit to AutoGenomics, Inc.’s registration statement on Form S-1 (Reg. No. 333-152512) (the “Registration Statement”), except as to the parties thereto, dates of issuance, principal
amounts and maturity dates set forth below. These other subordinated promissory notes are not being filed with the Registration Statement, pursuant to Instruction 2 to Item 601 of Regulation S-K promulgated under the Securities Exchange Act of
1934, as amended. 
  

											
	 Number
	 	 Holder
	 	 Date of Issuance
	 	Principal
Amount	 	 	 Maturity Date

	201003-002	 	A R Properties	 	March 9, 2010	 	$	125,000	  	 	March 10, 2012
	201003-003	 	IAS Management LLC	 	March 9, 2010	 	$	125,000	  	 	March 10, 2012
	201003-004	 	Lillian R. Kramer 2009 Trust	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-005	 	I Melvin Kramer Special Revocable Trust	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-006	 	Kim Pegula & Terrence Pegula, JT TEN	 	March 9, 2010	 	$	400,000	  	 	March 10, 2012
	201003-007	 	Brian J. Carruthers	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-008	 	Holder Enterprises, LLC	 	March 9, 2010	 	$	400,000	  	 	March 10, 2012
	201003-009	 	Sidney L. McDonald	 	March 9, 2010	 	$	400,000	  	 	March 10, 2012
	201003-010	 	Jeff Olson Consultant Retirement Trust	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-011	 	David Savula & Beverly Savula JTWROS	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-012	 	Stephen Lepley & Laura Jane Lepley, Ten. Com.	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-013	 	Ivie Family Limited Partnership	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-014	 	John David Wine	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-015	 	Mary Ann Evans	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-016	 	Woodford Farm Trust	 	March 9, 2010	 	$	250,000	  	 	March 10, 2012
	201003-017	 	Hubbard Properties	 	March 9, 2010	 	$	550,000	  	 	March 10, 2012
	201003-018	 	Carson Grantor Retained Annuity Trust	 	March 15, 2010	 	$	250,000	  	 	March 16, 2012Warrant to Purchase Common Stock (No. CS-05)

 Exhibit 10.14 
 THE SECURITIES EVIDENCED BY THIS WARRANT ARE RESTRICTED SECURITIES AND MAY NOT BE SOLD OR OFFERED FOR SALE EXCEPT IN COMPLIANCE WITH THE SECURITIES ACT OF 1933, AS AMENDED, AND ALL APPLICABLE STATE
SECURITIES LAWS. 
  

			
	WARRANT NO. CS-05	 	Date: March 21, 2007

 WARRANT TO PURCHASE COMMON STOCK 
 AutoGenomics, Inc., a California corporation (the “Company”), hereby certifies that AR Properties is entitled to purchase, on the terms and conditions contained herein, 150,000 shares
(the “Warrant Shares”) of the fully paid, validly issued and nonassessable Common Stock of the Company (the “Common Stock”), at an initial exercise price of $0.50 per Warrant Share (the “Exercise
Price”). The number of Warrant Shares and the Exercise Price are subject to adjustment as provided in Section 2 below. 
 This Warrant is subject to the following terms and conditions: 
 1.
Exercisability and Exercise. 
 1.1 Method of Exercise. This Warrant may be exercised in whole at the option of the
Holder at any time and from time to time from the date hereof through and including the fifth (5) year anniversary of the date hereof (the “Exercise Period”), by delivering to the Company payment of the aggregate Exercise Price
for the shares being purchased by check or wire transfer, together with an executed Notice of Exercise in the form attached hereto. 
 1.2 Effectiveness of Exercise; Procedure. The exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which the Holder delivers the
Notice of Exercise to the Company together with payment of the Exercise Price and satisfies all of the requirements of this Section 1. Upon such exercise, the Holder will be deemed a shareholder of record of the Warrant Shares with all rights
of a shareholder (including, without limitation, all voting rights with respect to such Warrant Shares and all rights to receive any dividends with respect to such Warrant Shares). In the event of any exercise of the rights represented by this
Warrant, certificates for the shares of Common Stock so purchased shall be delivered to the Holder within a reasonable time. The Company shall not be required to issue fractional shares upon the exercise of this Warrant. In lieu of any fractional
share to which the Holder would otherwise be entitled, the Holder shall be entitled, at its option, to receive either (a) a cash payment equal to the excess of the fair market value, as determined by the Board of Directors of the Company in
good faith, for such fractional share above the Exercise Price for such fractional share (as mutually determined by the Company and the Holder) or (b) a whole share if the Holder tenders the Exercise Price for one whole share. 

2. Adjustments. 
 2.1 Reorganizations, Mergers, Recapitalizations and Reclassifications. If, at any time after the date of this Warrant, (i) the outstanding shares of capital stock issuable upon exercise of
this Warrant are changed into, or exchanged for, a different number or kind of shares or securities of the Company through a reorganization, merger, recapitalization or reclassification, or (ii) the number of outstanding shares of such capital
stock is changed 

 
through a stock split, stock dividend, stock consolidation or similar capital adjustment, an appropriate adjustment shall be made by the Board, if necessary, in the Exercise Price and in the
number or kind of shares into which this Warrant is exercisable. In making such adjustments, or in determining that no such adjustments are necessary, the Board may rely upon the advice of counsel and accountants to the Company. 

2.2 Notice of Adjustment. Upon the occurrence of each adjustment or readjustment of the Exercise Price or the number and kind of
securities into which this Warrant is exercisable, the Company at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to the Holder a certificate setting forth such adjustment or
readjustment (including the kind and amount of securities, cash or other property for which this Warrant shall be exercisable and the Exercise Price) and showing in detail the facts upon which such adjustment or readjustment is based. The Company
shall, upon the written request at any time of the Holder, furnish or cause to be furnished to the Holder a certificate setting forth (i) the Exercise Price then in effect and (ii) the number and kind of shares of capital stock and the
amount, if any, of other securities, cash or property which then would be received upon the exercise of this Warrant. 
 3.
Reservation of Stock. The Company shall at all times have authorized, and reserved for the purpose of the issue upon exercise of this Warrant, a sufficient number of shares of its Common Stock to provide for the exercise of this Warrant.

 4. Exchange of Warrant. Upon the surrender by the Holder, properly endorsed, to the Company at the principal office of
the Company, the Company will issue and deliver to or upon the order of such Holder, at the Company’s expense, a new Warrant or Warrants of like tenor, in the name of the Holder or as the Holder may direct, without charge for any issuance or
transfer tax or other cost incurred by the Company, calling in the aggregate on the face or faces thereof for the number of shares of capital stock (or other securities, cash and/or property) then issuable upon exercise of this Warrant. The Company
will at no time close its transfer books against the transfer of the Warrant Shares issued or issuable upon the exercise of this Warrant in any manner which interferes with the timely exercise of this Warrant. 

5. Replacement of Warrant. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company, or (in the case of mutilation) upon
surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether
or not the Warrant so lost, stolen, destroyed or mutilated shall be at any time enforceable by anyone. 
 6. Transfer of
Warrant. This Warrant and all rights hereunder are transferable, in whole, upon surrender of this Warrant with a properly executed assignment (in the form of Exhibit II hereto) at the principal office of the Company. 

7. Miscellaneous. 
 7.1 Expiration. This Warrant shall expire at the close of business on the date which is five (5) years from the date hereof. 

  
 2 

 7.2 Restrictive Legend. This Warrant, any Warrant issued upon transfer of this
Warrant and the shares of Common Stock issued upon exercise of this Warrant shall be imprinted with substantially the following legend, in addition to any legends required under applicable state securities laws: 

“THE SECURITIES EVIDENCED BY THIS WARRANT / CERTIFICATE ARE RESTRICTED SECURITIES AND MAY NOT BE SOLD OR OFFERED FOR SALE EXCEPT IN
COMPLIANCE WITH THE SECURITIES ACT OF 1933, AS AMENDED, AND ALL APPLICABLE STATE SECURITIES LAWS.” 
 7.3 No Voting
Rights. Nothing contained in this Warrant shall be construed as conferring upon Holder by virtue of holding this Warrant (i) the right to vote or to consent as a shareholder in respect of meetings of shareholders for the election of
directors of the Company or any other matter, (ii) the right to receive dividends or (iii) any other rights as a shareholder of the Company. 
 7.4 Compliance with Securities Laws. Holder agrees to exercise this Warrant in compliance with all applicable federal and state securities laws and agrees to cooperate with the Company in taking
any and all action which may be deemed necessary or desirable to ensure such compliance, including, without limitation, the execution and delivery of one or more documents as requested by the Company representing as to certain matters and
acknowledging the restricted nature of the Common Stock to be issued. 
 7.5 Modification And Waiver. This Warrant and
any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement is sought. 
 7.6 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday or a Sunday or shall
be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a Saturday or a Sunday or a legal holiday. 
 7.7 Successors and Assigns. This Warrant shall be binding upon any successors or assigns of the Company. 

  
 3 

 [ Signature Page to Warrant to Purchase Common Stock ] 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed and issued by its duly authorized representative on the date first
above written. 
  

			
	AUTOGENOMICS, INC.
		
	By:	 	 /s/ Fareed Kureshy

		 	Fareed Kureshy,
		 	Its President and CEO

  
 4 

 Schedule to Exhibit 10.14 

The following common stock warrants are substantially identical in all material respects to the representative warrant to which this
schedule is attached and which is filed as an exhibit to AutoGenomics, Inc.’s registration statement on Form S-1 (the “Registration Statement”), except as to the parties thereto, dates of issuance, number of warrant shares, exercise
prices, vesting periods and expiration dates set forth below. These other common stock warrants are not being filed with the Registration Statement, pursuant to Instruction 2 to Item 601 of Regulation S-K promulgated under the Securities
Exchange Act of 1934, as amended. 
  

															
	 Number
	  	 Holder
	  	 Date of Issuance
	  	Warrant
Shares	 	  	Exercise Price
(per
share)	 	  	 Expiration Date

	 CS-06
	  	GenoMatrix India	  	May 5, 2008	  	 	50,000	  	  	$	0.60	  	  	May 6, 2013
		  	Dennis Repp	  	January 15, 2010	  	 	100,000	  	  	$	2.74	  	  	January 16, 2015
	 201010-001
	  	Michael J. Kiley	  	October 1, 2010	  	 	30,000	  	  	$	2.01	  	  	September 30, 2015
	 CS-07
	  	William Davidson	  	August 3, 2011	  	 	70,000	  	  	$	1.73	  	  	August 3, 2016
	 CS-08
	  	Thomas Testman	  	August 3, 2011	  	 	10,000	  	  	$	1.73	  	  	August 3, 2016
	 CS-09
	  	Laurence M. Demers	  	August 3, 2011	  	 	10,000	  	  	$	1.73	  	  	August 3, 2016
	 CS-10
	  	Dennis Repp	  	August 3, 2011	  	 	10,000	  	  	$	1.73	  	  	August 3, 2016
	 CS-11
	  	Yasemin Dalli	  	October 31, 2011	  	 	75,000	  	  	$	0.25	  	  	October 31, 2014
	 CS-12
	  	Stephen Allison	  	May 17, 2012	  	 	10,000	  	  	$	1.73	  	  	May 17, 2017
	 CS-13
	  	Laurence M. Demers	  	May 17, 2012	  	 	10,000	  	  	$	1.73	  	  	May 17, 2017
	 CS-14
	  	William Davidson	  	May 17, 2012	  	 	10,000	  	  	$	1.73	  	  	May 17, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]